C

CASI Pharmaceuticals Inc
NASDAQ:CASI

Watchlist Manager
CASI Pharmaceuticals Inc
NASDAQ:CASI
Watchlist
Price: 5.75 USD 3.6%
Market Cap: 77.1m USD
Have any thoughts about
CASI Pharmaceuticals Inc?
Write Note

CASI Pharmaceuticals Inc
Total Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

CASI Pharmaceuticals Inc
Total Liabilities Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Total Liabilities Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
C
CASI Pharmaceuticals Inc
NASDAQ:CASI
Total Liabilities
$51.1m
CAGR 3-Years
3%
CAGR 5-Years
67%
CAGR 10-Years
56%
Abbvie Inc
NYSE:ABBV
Total Liabilities
$137.4B
CAGR 3-Years
1%
CAGR 5-Years
15%
CAGR 10-Years
19%
Gilead Sciences Inc
NASDAQ:GILD
Total Liabilities
$36.1B
CAGR 3-Years
-7%
CAGR 5-Years
-1%
CAGR 10-Years
9%
Amgen Inc
NASDAQ:AMGN
Total Liabilities
$83.4B
CAGR 3-Years
14%
CAGR 5-Years
11%
CAGR 10-Years
6%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Liabilities
$6.6B
CAGR 3-Years
29%
CAGR 5-Years
24%
CAGR 10-Years
18%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Liabilities
$8.1B
CAGR 3-Years
8%
CAGR 5-Years
19%
CAGR 10-Years
21%

See Also

What is CASI Pharmaceuticals Inc's Total Liabilities?
Total Liabilities
51.1m USD

Based on the financial report for Dec 31, 2023, CASI Pharmaceuticals Inc's Total Liabilities amounts to 51.1m USD.

What is CASI Pharmaceuticals Inc's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
56%

Over the last year, the Total Liabilities growth was -1%. The average annual Total Liabilities growth rates for CASI Pharmaceuticals Inc have been 3% over the past three years , 67% over the past five years , and 56% over the past ten years .

Back to Top